Highland Capital Management LLC Lowers Stock Holdings in GSK plc (NYSE:GSK)

Highland Capital Management LLC lessened its holdings in GSK plc (NYSE:GSK) by 4.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 19,672 shares of the pharmaceutical company’s stock after selling 828 shares during the period. Highland Capital Management LLC’s holdings in GSK were worth $665,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of GSK. FMR LLC lifted its holdings in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after buying an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC lifted its stake in GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Clifford Capital Partners LLC boosted its holdings in shares of GSK by 14.3% during the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after purchasing an additional 51,378 shares during the last quarter. Cerity Partners LLC grew its position in shares of GSK by 61.8% during the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after purchasing an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC increased its holdings in shares of GSK by 20.0% in the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after purchasing an additional 83,433 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and dropped their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Six analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Stock Down 0.4 %

Shares of GSK stock opened at $35.20 on Friday. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The stock has a market cap of $72.96 billion, a price-to-earnings ratio of 22.86, a PEG ratio of 1.37 and a beta of 0.63. The firm’s 50-day moving average is $34.04 and its two-hundred day moving average is $37.71.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.